Home parenteral nutrition provision ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Home parenteral nutrition provision modalities for chronic intestinal failure in adult patients: an international survey
Author(s) :
Pironi, Loris [Auteur]
Steiger, Ezra [Auteur]
Brandt, Chrisoffer [Auteur]
Joly, Francisca [Auteur]
Wanten, Geert [Auteur]
Chambrier, Cecile [Auteur]
Aimasso, Umberto [Auteur]
Sasdelli, Anna Simona [Auteur]
Zeraschi, Sarah [Auteur]
Kelly, Darlene [Auteur]
Szczepanek, Kinga [Auteur]
Jukes, Amelia [Auteur]
Di Caro, Simona [Auteur]
Theilla, Miriam [Auteur]
Kunecki, Marek [Auteur]
Daniels, Joanne [Auteur]
Serlie, Mireille [Auteur]
Poullenot, Florian [Auteur]
Wu, Jian [Auteur]
Cooper, Sheldon C. [Auteur]
Rasmussen, Henrik H. [Auteur]
Compher, Charlene [Auteur]
Seguy, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Crivelli, Adriana [Auteur]
Pagano, Maria C. [Auteur]
Hughes, Sarah-Jane [Auteur]
Guglielmi, Francesco W. [Auteur]
Kozjek, Nada Rotovnik [Auteur]
Schneider, Stephane M. [Auteur]
Gillanders, Lyn [Auteur]
Ellegard, Lars [Auteur]
Thibault, Ronan [Auteur]
Université de Rennes [UR]
Matras, Przemyslaw [Auteur]
Zmarzly, Anna [Auteur]
Matysiak, Konrad [Auteur]
Van Gossum, Andre [Auteur]
Forbes, Alastair [Auteur]
Wyer, Nicola [Auteur]
Taus, Marina [Auteur]
Virgili, Nuria M. [Auteur]
O''''callaghan, Margie [Auteur]
Chapman, Brooke [Auteur]
Osland, Emma [Auteur]
Cuerda, Cristina [Auteur]
Sahin, Peter [Auteur]
Jones, Lynn [Auteur]
Won Lee, Andre Dong [Auteur]
Masconale, Luisa [Auteur]
Orlandoni, Paolo [Auteur]
Izbeki, Ferenc [Auteur]
Spaggiari, Corrado [Auteur]
Bueno, Marta [Auteur]
Doitchinova-Simeonova, Maryana [Auteur]
Garde, Carmen [Auteur]
Serralde-Zuniga, Aurora E. [Auteur]
Olveira, Gabriel [Auteur]
Krznaric, Zeljko [Auteur]
Czako, Laszlo [Auteur]
Kekstas, Gintautas [Auteur]
Sanz-Paris, Alejandro [Auteur]
Jauregui, Estrella Petrina [Auteur]
Murillo, Ana Zugasti [Auteur]
Schafer, Eszter [Auteur]
Arends, Jann [Auteur]
Suarez-Llanos, Jose P. [Auteur]
Lal, Simon [Auteur]
Steiger, Ezra [Auteur]
Brandt, Chrisoffer [Auteur]
Joly, Francisca [Auteur]
Wanten, Geert [Auteur]
Chambrier, Cecile [Auteur]
Aimasso, Umberto [Auteur]
Sasdelli, Anna Simona [Auteur]
Zeraschi, Sarah [Auteur]
Kelly, Darlene [Auteur]
Szczepanek, Kinga [Auteur]
Jukes, Amelia [Auteur]
Di Caro, Simona [Auteur]
Theilla, Miriam [Auteur]
Kunecki, Marek [Auteur]
Daniels, Joanne [Auteur]
Serlie, Mireille [Auteur]
Poullenot, Florian [Auteur]
Wu, Jian [Auteur]
Cooper, Sheldon C. [Auteur]
Rasmussen, Henrik H. [Auteur]
Compher, Charlene [Auteur]
Seguy, David [Auteur]

Lille Inflammation Research International Center - U 995 [LIRIC]
Crivelli, Adriana [Auteur]
Pagano, Maria C. [Auteur]
Hughes, Sarah-Jane [Auteur]
Guglielmi, Francesco W. [Auteur]
Kozjek, Nada Rotovnik [Auteur]
Schneider, Stephane M. [Auteur]
Gillanders, Lyn [Auteur]
Ellegard, Lars [Auteur]
Thibault, Ronan [Auteur]
Université de Rennes [UR]
Matras, Przemyslaw [Auteur]
Zmarzly, Anna [Auteur]
Matysiak, Konrad [Auteur]
Van Gossum, Andre [Auteur]
Forbes, Alastair [Auteur]
Wyer, Nicola [Auteur]
Taus, Marina [Auteur]
Virgili, Nuria M. [Auteur]
O''''callaghan, Margie [Auteur]
Chapman, Brooke [Auteur]
Osland, Emma [Auteur]
Cuerda, Cristina [Auteur]
Sahin, Peter [Auteur]
Jones, Lynn [Auteur]
Won Lee, Andre Dong [Auteur]
Masconale, Luisa [Auteur]
Orlandoni, Paolo [Auteur]
Izbeki, Ferenc [Auteur]
Spaggiari, Corrado [Auteur]
Bueno, Marta [Auteur]
Doitchinova-Simeonova, Maryana [Auteur]
Garde, Carmen [Auteur]
Serralde-Zuniga, Aurora E. [Auteur]
Olveira, Gabriel [Auteur]
Krznaric, Zeljko [Auteur]
Czako, Laszlo [Auteur]
Kekstas, Gintautas [Auteur]
Sanz-Paris, Alejandro [Auteur]
Jauregui, Estrella Petrina [Auteur]
Murillo, Ana Zugasti [Auteur]
Schafer, Eszter [Auteur]
Arends, Jann [Auteur]
Suarez-Llanos, Jose P. [Auteur]
Lal, Simon [Auteur]
Journal title :
Clinical Nutrition
Abbreviated title :
Clin Nutr
Volume number :
39
Pages :
585-591
Publication date :
2020-02
ISSN :
1532-1983
English keyword(s) :
Intravenous supplementation
Intestinal failure
Home parenteral nutrition
Cancer
Intestinal failure
Home parenteral nutrition
Cancer
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The safety and effectiveness of a home parenteral nutrition (HPN) program depends both on the expertise and the management approach of the HPN center. We aimed to evaluate both the approaches of different international ...
Show more >The safety and effectiveness of a home parenteral nutrition (HPN) program depends both on the expertise and the management approach of the HPN center. We aimed to evaluate both the approaches of different international HPN-centers in their provision of HPN and the types of intravenous supplementation (IVS)-admixtures prescribed to patients with chronic intestinal failure (CIF). In March 2015, 65 centers from 22 countries enrolled 3239 patients (benign disease 90.1%, malignant disease 9.9%), recording the patient, CIF and HPN characteristics in a structured database. The HPN-provider was categorized as health care system local pharmacy (LP) or independent home care company (HCC). The IVS-admixture was categorized as fluids and electrolytes alone (FE) or parenteral nutrition, either commercially premixed (PA) or customized to the individual patient (CA), alone or plus extra FE (PAFE or CAFE). Doctors of HPN centers were responsible for the IVS prescriptions. HCC (66%) was the most common HPN provider, with no difference noted between benign-CIF and malignant-CIF. LP was the main modality in 11 countries; HCC prevailed in 4 European countries: Israel, USA, South America and Oceania (p < 0.001). IVS-admixture comprised: FE 10%, PA 17%, PAFE 17%, CA 38%, CAFE 18%. PA and PAFE prevailed in malignant-CIF while CA and CAFE use was greater in benign-CIF (p < 0.001). PA + PAFE prevailed in those countries where LP was the main HPN-provider and CA + CAFE prevailed where the main HPN-provider was HCC (p < 0.001). This is the first study to demonstrate that HPN provision and the IVS-admixture differ greatly among countries, among HPN centers and between benign-CIF and cancer-CIF. As both HPN provider and IVS-admixture types may play a role in the safety and effectiveness of HPN therapy, criteria to homogenize HPN programs are needed so that patients can have equal access to optimal CIF care.Show less >
Show more >The safety and effectiveness of a home parenteral nutrition (HPN) program depends both on the expertise and the management approach of the HPN center. We aimed to evaluate both the approaches of different international HPN-centers in their provision of HPN and the types of intravenous supplementation (IVS)-admixtures prescribed to patients with chronic intestinal failure (CIF). In March 2015, 65 centers from 22 countries enrolled 3239 patients (benign disease 90.1%, malignant disease 9.9%), recording the patient, CIF and HPN characteristics in a structured database. The HPN-provider was categorized as health care system local pharmacy (LP) or independent home care company (HCC). The IVS-admixture was categorized as fluids and electrolytes alone (FE) or parenteral nutrition, either commercially premixed (PA) or customized to the individual patient (CA), alone or plus extra FE (PAFE or CAFE). Doctors of HPN centers were responsible for the IVS prescriptions. HCC (66%) was the most common HPN provider, with no difference noted between benign-CIF and malignant-CIF. LP was the main modality in 11 countries; HCC prevailed in 4 European countries: Israel, USA, South America and Oceania (p < 0.001). IVS-admixture comprised: FE 10%, PA 17%, PAFE 17%, CA 38%, CAFE 18%. PA and PAFE prevailed in malignant-CIF while CA and CAFE use was greater in benign-CIF (p < 0.001). PA + PAFE prevailed in those countries where LP was the main HPN-provider and CA + CAFE prevailed where the main HPN-provider was HCC (p < 0.001). This is the first study to demonstrate that HPN provision and the IVS-admixture differ greatly among countries, among HPN centers and between benign-CIF and cancer-CIF. As both HPN provider and IVS-admixture types may play a role in the safety and effectiveness of HPN therapy, criteria to homogenize HPN programs are needed so that patients can have equal access to optimal CIF care.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2024-01-30T10:28:24Z
2024-04-30T12:29:14Z
2024-04-30T12:29:14Z
Files
- document
- Open access
- Access the document